Search

Your search keyword '"Hanna, Nawar"' showing total 37 results
Start Over Author "Hanna, Nawar" Database Supplemental Index
37 results on '"Hanna, Nawar"'

1. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.

Author

Sun, Maxine, Cole, Alexander P., Hanna, Nawar, Mucci, Lorelei A., Berry, Donna L., Basaria, Shehzad, Ahern, David K., Kibel, Adam S., Choueiri, Toni K., and Trinh, Quoc-Dien

Subjects
ANDROGENS, PROSTATE cancer patients, COGNITION disorder risk factors, META-analysis, HEALTH outcome assessment
Abstract

Purpose Use of androgen deprivation therapy may increase the risk of cognitive impairment in men with prostate cancer. We performed a systematic review of the risk of overall cognitive impairment as an outcome in men receiving androgen deprivation therapy for prostate cancer. Materials and Methods Studies were identified through PubMed®, MEDLINE®, PsycINFO®, Cochrane Library and Web of Knowledge/Science™. Articles were included if they 1) were published in English, 2) had subjects treated for prostate cancer with androgen deprivation therapy, 3) incorporated longitudinal comparisons and 4) used control groups. In addition, prospective studies were required to assess an established cognitive related end point using International Cognition and Cancer Task Force criteria defining impaired cognitive performance as scoring 1.5 or more standard deviations below published norms on 2 or more tests, or scoring 2.0 or more standard deviations below published norms on at least 1 test. The effect of androgen deprivation therapy on cognitive impairment was pooled using a random effects model. Results Of 221 abstracts 26 were selected for full text review, and 2 prospective and 4 retrospective studies were analyzed. Androgen deprivation therapy was not associated with overall cognitive impairment when the prospective cohort studies were pooled (OR 1.57, 95% CI 0.50 to 4.92, p = 0.44) with significant heterogeneity between estimates (I 2 = 83%). In retrospective data the relative risk of any cognitive impairment, including senile dementia and Alzheimer disease, was increased in men receiving androgen deprivation therapy, although the difference was not statistically significant (HR 1.28, 95% CI 0.93 to 1.76, p = 0.13) with moderate heterogeneity between estimates (I 2 = 67%). Conclusions Analyses between overall cognitive impairment and use of androgen deprivation therapy defined according to International Cognition and Cancer Task Force criteria in a pooled analysis were inconclusive. In retrospective cohort studies the risk of overall cognitive impairment after androgen deprivation therapy was not significant. Better prospective studies need to be designed for the assessment of this end point. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

3. Factors Influencing Prostate Specific Antigen Testing in the United States

Author

von Landenberg, Nicolas, Mossanen, Matthew, Wang, Ye, Sammon, Jesse D., Hanna, Nawar, Gild, Philipp, Noldus, Joachim, Roghmann, Florian, Menon, Mani, Kibel, Adam S., Sun, Maxine, Chang, Steven L., and Trinh, Quoc-Dien

Abstract

Given the ongoing controversies regarding its benefit, prostate specific antigen based prostate cancer screening should be offered with patient preferences in mind. Understanding subsets of men who may or may not choose prostate specific antigen screening and their associated characteristics may allow more efficient care and may identify subsets of patients for whom additional counseling is warranted.

Published
2018
Full Text
View/download PDF

4. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA

Author

Hanna, Nawar, Trinh, Quoc-Dien, Seisen, Thomas, Vetterlein, Malte W., Sammon, Jesse, Preston, Mark A., Lipsitz, Stuart R., Bellmunt, Joaquim, Menon, Mani, Choueiri, Toni K., and Abdollah, Firas

Abstract

The use of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) is supported by results from several randomized control trials, including SWOG-8710.

Published
2018
Full Text
View/download PDF

8. Endobronchial Ultrasonography Added to Endoscopic Ultrasonography Improves Staging in Esophageal Cancer.

Author

Liberman, Moishe, Hanna, Nawar, Duranceau, André, Thiffault, Vicky, and Ferraro, Pasquale

Abstract

Background. The gold standard for staging the local extension (T stage) and lymph node (LN) status (N stage) of esophageal cancer is endoscopic ultrasonography (EUS). When biopsy of the peritumoral LNs is performed using EUS, there is a risk of specimen contamination secondary to piercing the primary tumor; this shortcoming can be circumvented with endobronchial ultrasonography (EBUS). Moreover, EBUS allows for biopsy of LN stations not accessible with EUS. Methods. The study consisted of a prospective clinical trial. Fifty-two consecutive patients with potentially resectable esophageal cancer referred for endoscopic staging were prospectively enrolled. Radial and convex EUS followed by convex EBUS were performed during a single staging procedure. The LNs not accessible by EUS were biopsied using EBUS. Results of the EBUS procedure were compared to those of EUS in terms of the addition of staging information, upstaging, and confirmation of stage. Results. The combined EBUS-EUS procedure was performed in 42 patients. Ten patients were excluded. In all, 54 LNs were biopsied under EUS guidance and 48 LNs were biopsied under EBUS guidance. The EUS results were positive for metastatic esophageal cancer in 29 LNs (54%), and EBUS was positive in 10 LNs (21%). The addition of EBUS to EUS in the staging of esophageal cancer led to nodal and patient upstaging in 5 patients (12%) and confirmed the EUS stage with additional negative or positive LN sampling in 29 patients (69%). Positive EBUS that led to upstaging (5 patients) changed the treatment plan from potentially resectable to palliative. There was no morbidity related to EBUS. Conclusions. A combined EBUS-EUS staging procedure improves precision in staging, leads to upstaging, and can change the treatment plan in patients with esophageal cancer. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

9. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

Author

Alasker, Ahmed, Meskawi, Malek, Sun, Maxine, Ismail, Salima, Hanna, Nawar, Hansen, Jens, Tian, Zhe, Bianchi, Marco, Perrotte, Paul, and Karakiewicz, Pierre I.

Abstract

Abstract: Background: To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management. Materials and methods: We performed a PubMed and Cochrane-based review of side effects associated with the seven agents including product monographs to provide an outline of treatment measures aiming to reduce their toxicities. Subject and outcome of interest, design type, sample size, pertinence and quality, and detail of reporting were the indicators of manuscript quality. Results: All targeted therapies cause adverse events. Most adverse events may be prevented or tested before they escalate to severe levels. Conclusion: Prevention, early recognition, and prompt management of side effects are of key importance and avoid unnecessary dose reductions, which may undermine treatment efficacy. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

10. FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients

Author

Meskawi, Malek, Sun, Maxine, Ismail, Salima, Bianchi, Marco, Hansen, Jens, Tian, Zhe, Hanna, Nawar, Trinh, Quoc-Dien, Graefen, Markus, Montorsi, Francesco, Perrotte, Paul, and Karakiewicz, Pierre I

Abstract

Our objective was to test whether FG (FG) is applicable in the context of chromophobe renal cell carcinoma patients treated with partial and radical nephrectomy. Patients (n=1862) with chromophobe renal cell carcinoma treated with partial and radical nephrectomy were identified within the Surveillance, Epidemiology, and End Results (1988–2008). Univariable and multivariable Cox regression analyses were fitted to predict cancer-specific mortality. Discriminant properties were assessed for the conventional four-tiered FG scheme. Additionally, discrimination of the three-tiered FG scheme (1–2 vs3 vs4) and the two-tiered FG scheme (1–2 vs3–4) was also assessed. The statistical significance of the differences in accuracy estimates was compared using the Mantel–Haenszel test. A total of 65 of the 1862 died of the disease. The overall 5-year cancer-specific mortality-free survival rate was 94.8% (95% confidence interval: 93.5–96.2). In univariable analyses, none of the FG strata were significantly associated with cancer-specific mortality. Furthermore, FG was less informative (63%) than tumor size (72%) and tumor stage (69%), using measures of discrimination in univariable analyses. After accounting for all covariates, prediction of 5-year cancer-specific mortality was 79.0% vs80.3% accurate, respectively, with vswithout the consideration of FG (P=0.01). Similar discrimination estimates were obtained for the modified three-tiered FG scheme (78.5%; P=0.009) and the modified two-tiered FG scheme (79.5%; P=0.02). In conclusion, FG is not an informative predictor of prognosis, defined as cancer-specific mortality, after partial and radical nephrectomy for chromophobe renal cell carcinoma patients.

Published
2013
Full Text
View/download PDF

11. FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients

Author

Meskawi, Malek, Sun, Maxine, Ismail, Salima, Bianchi, Marco, Hansen, Jens, Tian, Zhe, Hanna, Nawar, Trinh, Quoc-Dien, Graefen, Markus, Montorsi, Francesco, Perrotte, Paul, and Karakiewicz, Pierre I

Abstract

Our objective was to test whether FG (FG) is applicable in the context of chromophobe renal cell carcinoma patients treated with partial and radical nephrectomy. Patients (n=1862) with chromophobe renal cell carcinoma treated with partial and radical nephrectomy were identified within the Surveillance, Epidemiology, and End Results (1988–2008). Univariable and multivariable Cox regression analyses were fitted to predict cancer-specific mortality. Discriminant properties were assessed for the conventional four-tiered FG scheme. Additionally, discrimination of the three-tiered FG scheme (1–2 vs 3 vs 4) and the two-tiered FG scheme (1–2 vs 3–4) was also assessed. The statistical significance of the differences in accuracy estimates was compared using the Mantel–Haenszel test. A total of 65 of the 1862 died of the disease. The overall 5-year cancer-specific mortality-free survival rate was 94.8% (95% confidence interval: 93.5–96.2). In univariable analyses, none of the FG strata were significantly associated with cancer-specific mortality. Furthermore, FG was less informative (63%) than tumor size (72%) and tumor stage (69%), using measures of discrimination in univariable analyses. After accounting for all covariates, prediction of 5-year cancer-specific mortality was 79.0% vs 80.3% accurate, respectively, with vs without the consideration of FG (P=0.01). Similar discrimination estimates were obtained for the modified three-tiered FG scheme (78.5%; P=0.009) and the modified two-tiered FG scheme (79.5%; P=0.02). In conclusion, FG is not an informative predictor of prognosis, defined as cancer-specific mortality, after partial and radical nephrectomy for chromophobe renal cell carcinoma patients.

Published
2013
Full Text
View/download PDF

36. Erratum: FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients

Author

Meskawi, Malek, Sun, Maxine, Ismail, Salima, Bianchi, Marco, Hansen, Jens, Tian, Zhe, Hanna, Nawar, Trinh, Quoc-Dien, Graefen, Markus, Montorsi, Francesco, Perrotte, Paul, and Karakiewicz, Pierre I

Abstract

Correction to: Modern Pathology advance online publication, 1 February 2013; doi: 10.1038/modpathol.2012.230 The title of this article should be 'Fuhrman grade has no added value in prediction of mortality after partial or radical nephrectomy for chromophobe renal cell carcinoma patients.' The firstsentence of the abstract should be 'Our objective was to test whether Fuhrman grade (FG) is applicable in the context of chromophobe renal cell carcinoma patients treated with partial and radical nephrectomy.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results